Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Bags Exclusive Rights To Develop, Sell Debiopharm’s Xevinapant

The IAP antagonist Is In Phase III Trials For Head And Neck Cancer

Executive Summary

Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.

You may also be interested in...



Merck KGaA Plumps For Reinvention To Refuel R&D

The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.

Merck KGaA Overcomes Ukraine Disruption To Keep MS Frontrunner On Track

The German group is optimistic evobrutinib can be a blockbuster in multiple sclerosis and has adapted its pivotal trial to cope with disruption caused by the war in Ukraine.

Merck KGaA Keeps Powder Dry On Licensing Deals

After doing a number of healthcare deals in 2021, it looks as though Merck KGaA will keep M&A activity to a minimum for the division this year, focusing instead on advancing its own promising candidates for cancer, multiple sclerosis and lupus.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143906

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel